Here's How Much Upside Eli Lilly Stock Has, According to Analysts

When a stock has been soaring in value, it can be difficult to determine if it's still a good buy and has much more room to rise, or if it may be approaching a peak. This is especially true when investors are paying a premium for a business, as concerns may mount about its valuation.Eli Lilly (NYSE: LLY) is a great example of that, with the healthcare giant amassing returns of around 400% in the past five years; it now trades at approximately 40 times its trailing earnings, and its market cap is north of $800 billion. It has a fairly high valuation, but given its terrific growth opportunities, it may still be worth investing in.One way to gauge how much upside a stock may have left is by looking at analyst price targets. While they aren't perfect, they can give investors a good indication of whether the stock may still be worth investing in. Here's how bullish analysts are about Eli Lilly right now.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool